Positron emission tomography with 18F-fluciclovine to predict recurrence in post-treatment recurrent prostate cancer and its role in altering treatment plans.
Chong J, Muhleman M, Say R, Kostakoglu L, Ahmed J, Tewari A, Stock R, Oh W. Positron emission tomography with 18F-fluciclovine to predict recurrence in post-treatment recurrent prostate cancer and its role in altering treatment plans. Journal Of Clinical Oncology 2019, 37: 214-214. DOI: 10.1200/jco.2019.37.7_suppl.214.Peer-Reviewed Original ResearchStereotactic body radiation therapyPSA cut-offRecurrent prostate cancerRadiographic recurrenceTreatment planningPositive scansSalvage therapyProstate cancerAlteration of treatment planAltering treatment plansSalvage surgical therapyCut-offPositron emission tomographyProstate bedRadiation therapyRecurrence siteSurgical therapyLymph nodesTreatment alterationsRadiographic diseasePET/CTRecurrenceTreatment changesRisk factorsTherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply